Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.

BMC pulmonary medicine - 17 Apr 2021

Zhang Lei, Liu Huanhuan, Tian Ye, Wang Huina, Yang Xueying

Abstract excerpt

BACKGROUND: The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor. It is not clear whether the NTRK breakpoint location is different for response to targeted therapy and NTRK fusions affects the efficacy of immunotherapy. CASE PRESENTATION: Here we reported a 60-year-old female diagnosed with advanced lung adenocarcinoma....

Topics

Join the communities discussing this publication.

Adenocarcinoma of Lung
Lung Neoplasms
Mutation
Protein Kinase Inhibitors
Pyrazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 33865348
DOI: 10.1186/s12890-021-01490-x
PMCID: PMC8052639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.PMID 33865348Read ↗

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor ResistanceSemantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

NTRK gene fusion testing and management in lung cancerSemantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in ChinaSemantic proximity Read ↗

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese populationSemantic proximity Read ↗

TRK Inhibition: A New Tumor-Agnostic Treatment StrategySemantic proximity Read ↗

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read ↗

NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.Semantic proximity Read ↗

A Case of NTRK Gene Mutation in Non-Small Cell Lung Cancer and Literature ReviewSemantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.